Global Neurometabolic Disorders Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Table of Contents

1 Neurometabolic Disorders Market Overview

• 1.1 Product Overview and Scope of Neurometabolic Disorders
• 1.2 Classification of Neurometabolic Disorders by Types
  • 1.2.1 Global Neurometabolic Disorders Revenue Comparison by Types (2019-2024)
  • 1.2.2 Global Neurometabolic Disorders Revenue Market Share by Types in 2018
  • 1.2.3 Gaucher’s Disease
  • 1.2.4 Fabry Disease
  • 1.2.5 Pompe Disease
  • 1.2.6 Mucopolysaccharidosis VI
  • 1.2.7 Other
• 1.3 Global Neurometabolic Disorders Market by Application
  • 1.3.1 Global Neurometabolic Disorders Market Size and Market Share Comparison by Applications (2014-2024)
  • 1.3.2 Oral
  • 1.3.3 Parenteral
• 1.4 Global Neurometabolic Disorders Market by Regions
  • 1.4.1 Global Neurometabolic Disorders Market Size (Million USD) Comparison by Regions (2014-2024)
  • 1.4.1 North America (USA, Canada and Mexico) Neurometabolic Disorders Status and Prospect (2014-2024)
  • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Neurometabolic Disorders Status and Prospect (2014-2024)
  • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Neurometabolic Disorders Status and Prospect (2014-2024)
  • 1.4.4 South America (Brazil, Argentina, Colombia) Neurometabolic Disorders Status and Prospect (2014-2024)
  • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Neurometabolic Disorders Status and Prospect (2014-2024)
• 1.5 Global Market Size of Neurometabolic Disorders (2014-2024)

2 Company Profiles

• 2.1 Amicus Therapeutics
  • 2.1.1 Business Overview
  • 2.1.2 Neurometabolic Disorders Type and Applications
    • 2.1.2.1 Product A
    • 2.1.2.2 Product B
  • 2.1.3 Amicus Therapeutics Neurometabolic Disorders Revenue, Gross Margin and Market Share (2017-2018)
• 2.2 ExSAR Corporation
  • 2.2.1 Business Overview
  • 2.2.2 Neurometabolic Disorders Type and Applications
    • 2.2.2.1 Product A
    • 2.2.2.2 Product B
  • 2.2.3 ExSAR Corporation Neurometabolic Disorders Revenue, Gross Margin and Market Share (2017-2018)
• 2.3 Biosidus
  • 2.3.1 Business Overview
  • 2.3.2 Neurometabolic Disorders Type and Applications
    • 2.3.2.1 Product A
    • 2.3.2.2 Product B
  • 2.3.3 Biosidus Neurometabolic Disorders Revenue, Gross Margin and Market Share (2017-2018)
• 2.4 ISU Abxis
  • 2.4.1 Business Overview
  • 2.4.2 Neurometabolic Disorders Type and Applications
    • 2.4.2.1 Product A
    • 2.4.2.2 Product B
  • 2.4.3 ISU Abxis Neurometabolic Disorders Revenue, Gross Margin and Market Share (2017-2018)
• 2.5 Dong-A Socio Group
  • 2.5.1 Business Overview
  • 2.5.2 Neurometabolic Disorders Type and Applications
    • 2.5.2.1 Product A
    • 2.5.2.2 Product B
  • 2.5.3 Dong-A Socio Group Neurometabolic Disorders Revenue, Gross Margin and Market Share (2017-2018)
• 2.6 JCR Pharmaceuticals
  • 2.6.1 Business Overview
  • 2.6.2 Neurometabolic Disorders Type and Applications
    • 2.6.2.1 Product A
    • 2.6.2.2 Product B
  • 2.6.3 JCR Pharmaceuticals Neurometabolic Disorders Revenue, Gross Margin and Market Share (2017-2018)
• 2.7 Neuraltus Pharmaceuticals
  • 2.7.1 Business Overview
  • 2.7.2 Neurometabolic Disorders Type and Applications
    • 2.7.2.1 Product A
    • 2.7.2.2 Product B
  • 2.7.3 Neuraltus Pharmaceuticals Neurometabolic Disorders Revenue, Gross Margin and Market Share (2017-2018)
• 2.8 UAB Proforma
  • 2.8.1 Business Overview
  • 2.8.2 Neurometabolic Disorders Type and Applications
    • 2.8.2.1 Product A
    • 2.8.2.2 Product B
  • 2.8.3 UAB Proforma Neurometabolic Disorders Revenue, Gross Margin and Market Share (2017-2018)
• 2.9 Greenovation Biotech
  • 2.9.1 Business Overview
  • 2.9.2 Neurometabolic Disorders Type and Applications
    • 2.9.2.1 Product A
    • 2.9.2.2 Product B
  • 2.9.3 Greenovation Biotech Neurometabolic Disorders Revenue, Gross Margin and Market Share (2017-2018)
• 2.10 Lixte Biotechnology
  • 2.10.1 Business Overview
  • 2.10.2 Neurometabolic Disorders Type and Applications
    • 2.10.2.1 Product A
    • 2.10.2.2 Product B
  • 2.10.3 Lixte Biotechnology Neurometabolic Disorders Revenue, Gross Margin and Market Share (2017-2018)
• 2.11 Biomarin
  • 2.11.1 Business Overview
  • 2.11.2 Neurometabolic Disorders Type and Applications
    • 2.11.2.1 Product A
    • 2.11.2.2 Product B
  • 2.11.3 Biomarin Neurometabolic Disorders Revenue, Gross Margin and Market Share (2017-2018)
• 2.12 Greencross
  • 2.12.1 Business Overview
  • 2.12.2 Neurometabolic Disorders Type and Applications
    • 2.12.2.1 Product A
    • 2.12.2.2 Product B
  • 2.12.3 Greencross Neurometabolic Disorders Revenue, Gross Margin and Market Share (2017-2018)
• 2.13 Protalix
  • 2.13.1 Business Overview
  • 2.13.2 Neurometabolic Disorders Type and Applications
    • 2.13.2.1 Product A
    • 2.13.2.2 Product B
  • 2.13.3 Protalix Neurometabolic Disorders Revenue, Gross Margin and Market Share (2017-2018)
• 2.14 Genzyme
  • 2.14.1 Business Overview
  • 2.14.2 Neurometabolic Disorders Type and Applications
    • 2.14.2.1 Product A
    • 2.14.2.2 Product B
  • 2.14.3 Genzyme Neurometabolic Disorders Revenue, Gross Margin and Market Share (2017-2018)
• 2.15 Amicus
  • 2.15.1 Business Overview
  • 2.15.2 Neurometabolic Disorders Type and Applications
    • 2.15.2.1 Product A
    • 2.15.2.2 Product B
  • 2.15.3 Amicus Neurometabolic Disorders Revenue, Gross Margin and Market Share (2017-2018)
• 2.16 Pharming Group
  • 2.16.1 Business Overview
  • 2.16.2 Neurometabolic Disorders Type and Applications
    • 2.16.2.1 Product A
    • 2.16.2.2 Product B
  • 2.16.3 Pharming Group Neurometabolic Disorders Revenue, Gross Margin and Market Share (2017-2018)
• 2.17 Shire
  • 2.17.1 Business Overview
  • 2.17.2 Neurometabolic Disorders Type and Applications
    • 2.17.2.1 Product A
    • 2.17.2.2 Product B
  • 2.17.3 Shire Neurometabolic Disorders Revenue, Gross Margin and Market Share (2017-2018)
• 2.18 Protalix BioTherapeutics
  • 2.18.1 Business Overview
  • 2.18.2 Neurometabolic Disorders Type and Applications
    • 2.18.2.1 Product A
    • 2.18.2.2 Product B
  • 2.18.3 Protalix BioTherapeutics Neurometabolic Disorders Revenue, Gross Margin and Market Share (2017-2018)

3 Global Neurometabolic Disorders Market Competition, by Players

• 3.1 Global Neurometabolic Disorders Revenue and Share by Players (2014-2019)
• 3.2 Market Concentration Rate
  • 3.2.1 Top 5 Neurometabolic Disorders Players Market Share
  • 3.2.2 Top 10 Neurometabolic Disorders Players Market Share
• 3.3 Market Competition Trend

4 Global Neurometabolic Disorders Market Size by Regions

• 4.1 Global Neurometabolic Disorders Revenue and Market Share by Regions
• 4.2 North America Neurometabolic Disorders Revenue and Growth Rate (2014-2019)
• 4.3 Europe Neurometabolic Disorders Revenue and Growth Rate (2014-2019)
• 4.4 Asia-Pacific Neurometabolic Disorders Revenue and Growth Rate (2014-2019)
• 4.5 South America Neurometabolic Disorders Revenue and Growth Rate (2014-2019)
• 4.6 Middle East and Africa Neurometabolic Disorders Revenue and Growth Rate (2014-2019)

5 North America Neurometabolic Disorders Revenue by Countries

• 5.1 North America Neurometabolic Disorders Revenue by Countries (2014-2019)
• 5.2 USA Neurometabolic Disorders Revenue and Growth Rate (2014-2019)
• 5.3 Canada Neurometabolic Disorders Revenue and Growth Rate (2014-2019)
• 5.4 Mexico Neurometabolic Disorders Revenue and Growth Rate (2014-2019)

6 Europe Neurometabolic Disorders Revenue by Countries

• 6.1 Europe Neurometabolic Disorders Revenue by Countries (2014-2019)
• 6.2 Germany Neurometabolic Disorders Revenue and Growth Rate (2014-2019)
• 6.3 UK Neurometabolic Disorders Revenue and Growth Rate (2014-2019)
• 6.4 France Neurometabolic Disorders Revenue and Growth Rate (2014-2019)
• 6.5 Russia Neurometabolic Disorders Revenue and Growth Rate (2014-2019)
• 6.6 Italy Neurometabolic Disorders Revenue and Growth Rate (2014-2019)

7 Asia-Pacific Neurometabolic Disorders Revenue by Countries

• 7.1 Asia-Pacific Neurometabolic Disorders Revenue by Countries (2014-2019)
• 7.2 China Neurometabolic Disorders Revenue and Growth Rate (2014-2019)
• 7.3 Japan Neurometabolic Disorders Revenue and Growth Rate (2014-2019)
• 7.4 Korea Neurometabolic Disorders Revenue and Growth Rate (2014-2019)
• 7.5 India Neurometabolic Disorders Revenue and Growth Rate (2014-2019)
• 7.6 Southeast Asia Neurometabolic Disorders Revenue and Growth Rate (2014-2019)

8 South America Neurometabolic Disorders Revenue by Countries

• 8.1 South America Neurometabolic Disorders Revenue by Countries (2014-2019)
• 8.2 Brazil Neurometabolic Disorders Revenue and Growth Rate (2014-2019)
• 8.3 Argentina Neurometabolic Disorders Revenue and Growth Rate (2014-2019)
• 8.4 Colombia Neurometabolic Disorders Revenue and Growth Rate (2014-2019)

9 Middle East and Africa Revenue Neurometabolic Disorders by Countries

• 9.1 Middle East and Africa Neurometabolic Disorders Revenue by Countries (2014-2019)
• 9.2 Saudi Arabia Neurometabolic Disorders Revenue and Growth Rate (2014-2019)
• 9.3 UAE Neurometabolic Disorders Revenue and Growth Rate (2014-2019)
• 9.4 Egypt Neurometabolic Disorders Revenue and Growth Rate (2014-2019)
• 9.5 Nigeria Neurometabolic Disorders Revenue and Growth Rate (2014-2019)
• 9.6 South Africa Neurometabolic Disorders Revenue and Growth Rate (2014-2019)

10 Global Neurometabolic Disorders Market Segment by Type

• 10.1 Global Neurometabolic Disorders Revenue and Market Share by Type (2014-2019)
• 10.2 Global Neurometabolic Disorders Market Forecast by Type (2019-2024)
• 10.3 Gaucher’s Disease Revenue Growth Rate (2014-2024)
• 10.4 Fabry Disease Revenue Growth Rate (2014-2024)
• 10.5 Pompe Disease Revenue Growth Rate (2014-2024)
• 10.6 Mucopolysaccharidosis VI Revenue Growth Rate (2014-2024)
• 10.7 Other Revenue Growth Rate (2014-2024)

11 Global Neurometabolic Disorders Market Segment by Application

• 11.1 Global Neurometabolic Disorders Revenue Market Share by Application (2014-2019)
• 11.2 Neurometabolic Disorders Market Forecast by Application (2019-2024)
• 11.3 Oral Revenue Growth (2014-2019)
• 11.4 Parenteral Revenue Growth (2014-2019)

12 Global Neurometabolic Disorders Market Size Forecast (2019-2024)

• 12.1 Global Neurometabolic Disorders Market Size Forecast (2019-2024)
• 12.2 Global Neurometabolic Disorders Market Forecast by Regions (2019-2024)
• 12.3 North America Neurometabolic Disorders Revenue Market Forecast (2019-2024)
• 12.4 Europe Neurometabolic Disorders Revenue Market Forecast (2019-2024)
• 12.5 Asia-Pacific Neurometabolic Disorders Revenue Market Forecast (2019-2024)
• 12.6 South America Neurometabolic Disorders Revenue Market Forecast (2019-2024)
• 12.7 Middle East and Africa Neurometabolic Disorders Revenue Market Forecast (2019-2024)

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology